← Back to Search
Paclitaxel- And Lapatinib-loaded Lipopolymer Micelles Overcome Multidrug Resistance In Prostate Cancer
Feng Li, M. Danquah, S. Singh, H. Wu, R. Mahato
Published 2011 · Medicine
Download PDFAnalyze on Scholarcy
Paclitaxel is a potent chemotherapeutic agent for treating refractory prostate cancer. However, its prolonged treatment develops multidrug resistance. Since lapatinib interacts with and inhibits P-gp activity, our objective was to determine whether the combination therapy of these two drugs can synergistically treat resistant prostate cancer. Our recently synthesized lipopolymer, poly(ethylene glycol)-block-poly(2-methyl-2-carboxylpropylene carbonate-graft-dodecanol) (PEG–PCD), was used to efficiently load both drugs into PEG–PCD micelles since they are hydrophobic. Lapatinib inhibited P-gp function but not its expression. Co-treatment of DU145-TXR cells with 0.5 μM paclitaxel and 5 μM lapatinib resulted in up to 138-fold reversal compared to paclitaxel alone. These formulations killed almost 70% and 80% of DU145-TXR cells when 0.5 μM paclitaxel was combined with lapatinib at a dose of 1 and 5 μM, respectively, while monotherapy had no effect. Combination therapy induced apoptosis and cell cycle arrest at mitotic phase. Xenograft tumor growth in athymic nude mice was significantly regressed when PEG–PCD micelles carrying lapatinib and paclitaxel were given intravenously twice a week. Furthermore, this combination therapy synergistically decreased antiangiogenic activity compared to the control or their monotherapy. In conclusion, lipopolymeric micelles carrying lapatinib and paclitaxel have the potential to treat resistant prostate cancer and can successfully deliver drugs to tumors while minimizing toxic effects associated with solubilizing agents.
This paper references
Paclitaxel‐induced cell death
T. Wang (2000)
Inhibition of HER-2/neu kinase impairs androgen receptor recruitment to the androgen responsive enhancer.
Y. Liu (2005)
Targeting multidrug resistance in cancer
G. Szakács (2006)
The HER tyrosine kinase inhibitor CI1033 enhances cytotoxicity of 7-ethyl-10-hydroxycamptothecin and topotecan by inhibiting breast cancer resistance protein-mediated drug efflux.
C. Erlichman (2001)
Synthesis, formulation and in vitro evaluation of a novel microtubule destabilizer, SMART-100.
F. Li (2010)
Tyrosine kinase inhibitors potentiate the cytotoxicity of MDR-substrate anticancer agents independent of growth factor receptor status in lung cancer cell lines
D. Collins (2009)
What are determining factors for stable drug incorporation into polymeric micelle carriers? Consideration on physical and chemical characters of the micelle inner core.
Tatsuhiro Yamamoto (2007)
Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer.
A. Di Leo (2008)
Multidrug Resistance in Prostate Cancer
J. V. van Brussel (2003)
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review.
H. Maeda (2000)
Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs
C. Sánchez (2009)
Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery.
F. Li (2010)
Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
X-b Li (2008)
Liposome-mediated modulation of multidrug resistance in human HL-60 leukemia cells.
A. Rahman (1992)
Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
Chun-ling Dai (2008)
Expression of multidrug resistance proteins in prostate cancer is related with cell sensitivity to chemotherapeutic drugs. Prostate
C Sanchez (2009)
Polymeric micellar paclitaxel phosphorylates Bcl‐2 and induces apoptotic regression of androgen‐independent LNCaP prostate tumors
S. Leung (2000)
Role of the MDR-1-encoded multiple drug resistance phenotype in prostate cancer cell lines.
G. Theyer (1993)
Copoly(styrene-maleic acid)-pirarubicin micelles: high tumor-targeting efficiency with little toxicity.
K. Greish (2005)
Doxorubicin and paclitaxel-loaded lipid-based nanoparticles overcome multidrug resistance by inhibiting P-glycoprotein and depleting ATP.
X. Dong (2009)
Synthesis and characterization of amphiphilic lipopolymers for micellar drug delivery. Biomacromolecules
F Li (2010)
A Multicenter Phase II Clinical Trial of Lapatinib (GW572016) in Hormonally Untreated Advanced Prostate Cancer
S. Sridhar (2010)
The microtubule-affecting drug paclitaxel has antiangiogenic activity.
D. Belotti (1996)
Small Molecule Tyrosine Kinase Inhibitors in the Treatment of Solid Tumors: An Update of Recent Developments
N. Steeghs (2006)
Inhibition of androgen-independent prostate cancer cell growth is enhanced by combination therapy targeting Hedgehog and ErbB signalling
G. Shaw (2007)
an update of recent developments
N Steeghs (2011)
Lapatinib and erlotinib are potent reversal agents for MRP7 (ABCC10)-mediated multidrug resistance.
Yehong Kuang (2010)
Modulation of P-gp expression by lapatinib
Gráinne Dunne (2010)
HPMA copolymer bound adriamycin overcomes MDR1 gene encoded resistance in a human ovarian carcinoma cell line.
T. Minko (1998)
Receptor tyrosine kinase (RTK) inhibition is effective in chemosensitising EGFR-expressing drug resistant human ovarian cancer cell lines when used in combination with cytotoxic agents.
H. Coley (2006)
Lapatinib: a dual inhibitor of human epidermal growth factor receptor tyrosine kinases.
P. Medina (2008)
Extravasation of polymeric nanomedicines across tumor vasculature.
M. Danquah (2011)
Tyrosine kinase inhibitor gefitinib enhances topotecan penetration of gliomas.
A. Carcaboso (2010)
Expression of multidrug resistance proteins in
This paper is referenced by
Nanotherapies for treating prostate cancer
M. Danquah (2012)
Biomimetic metal-organic nanoparticles prepared with a 3D-printed microfluidic device as a novel formulation for disulfiram-based therapy against breast cancer
Y. Chang (2020)
Old wine in new bottles: Advanced drug delivery systems for disulfiram-based cancer therapy.
Anne McMahon (2020)
Formulation and Characterization of Polyester/Polycarbonate Nanoparticles for Delivery of a Novel Microtubule Destabilizing Agent
Vaibhav Mundra (2012)
Combination Therapy of Antiandrogen and XIAP Inhibitor for Treating Advanced Prostate Cancer
M. Danquah (2012)
Dual Inhibitors as a New Challenge for Cancer Multidrug Resistance Treatment.
Tijana Stankovic (2018)
A novel combined micellar system of lapatinib and Paclitaxel with enhanced antineoplastic effect against human epidermal growth factor receptor-2 positive breast tumor in vitro.
Y. Wei (2015)
Reversal of P-Glycoprotein and Breast Cancer Resistance Protein Mediated Multidrug Resistance In Vitro Using In Silico Identified Novel Compounds
A. Nanayakkara (2019)
Pluronic F127 polymeric micelles for co-delivery of paclitaxel and lapatinib against metastatic breast cancer: preparation, optimization and in vitro evaluation
Pooya Dehghan Kelishady (2015)
Exosome-derived microRNAs contribute to prostate cancer chemoresistance.
Jing Li (2016)
NMR study of the supramolecular structure of dual drug-loaded poly(butylcyanoacrylate) nanoparticles.
M. Simeonova (2013)
Cytotoxic Effect of Paclitaxel and Lapatinib Co-Delivered in Polylactide-co-Poly(ethylene glycol) Micelles on HER-2-Negative Breast Cancer Cells
A. Zajdel (2019)
Rapid Self-Assembly of Polymer Nanoparticles for Synergistic Codelivery of Paclitaxel and Lapatinib via Flash NanoPrecipitation
Shani L. Levit (2020)
In vitro and in vivo evaluation of paclitaxel–lapatinib-loaded F127 pluronic micelles
Pouya Dehghankelishadi (2017)
Chemoresistance in Prostate Cancer Cells Is Regulated by miRNAs and Hedgehog Pathway
S. Singh (2012)
Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles.
F. Li (2016)
A novel localized co-delivery system with lapatinib microparticles and paclitaxel nanoparticles in a peritumorally injectable in situ hydrogel.
Hongxiang Hu (2015)
Anticancer efficacy and toxicokinetics of a novel paclitaxel-clofazimine nanoparticulate co-formulation
Dwayne Koot (2015)
Tumour vasculature targeted anti-cancer therapy
Debabrata G Dastidar (2020)
Delivery of small molecule and RNA for the treatment of type 1 diabetes and prostate cancer
Di Wen (2017)
Lipid‐polymer hybrid nanocarriers for delivering cancer therapeutics
Tushar Date (2018)
Advances in nanotechnology-based delivery systems for EGFR tyrosine kinases inhibitors in cancer therapy
Xiaohan Zhou (2020)
Lapatinib nano-delivery systems: a promising future for breast cancer treatment
G. Bonde (2018)
Paclitaxel/sunitinib-loaded micelles promote an antitumor response in vitro through synergistic immunogenic cell death for triple-negative breast cancer.
T. Qin (2020)
Application of Prostate Cancer Models for Preclinical Study: Advantages and Limitations of Cell Lines, Patient-Derived Xenografts, and Three-Dimensional Culture of Patient-Derived Cells
Takeshi Namekawa (2019)
Co-delivery of Cell-permeable Chimeric Apoptosis AVPIR8 Peptide/p53 DNA for Cocktail Therapy
H. Wang (2013)
Doxorubicin and lapatinib combination nanomedicine for treating resistant breast cancer.
H. Wang (2014)
Lactic Acid- and Carbonate-Based Crosslinked Polymeric Micelles for Drug Delivery
M. Danquah (2013)
Programmable Delivery of Synergistic Cancer Drug Combinations Using Bicompartmental Nanoparticles.
Jason V Gregory (2020)
Synergistic Antitumor Effects on Drug-Resistant Breast Cancer of Paclitaxel/Lapatinib Composite Nanocrystals
J. Wang (2020)